EQL Pharma AB (publ) (STO:EQL)

Market Cap	1.71B
Revenue (ttm)	399.07M
Net Income (ttm)	29.61M
Shares Out	29.53M
EPS (ttm)	0.98
PE Ratio	59.27
Forward PE	35.57
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,661
Average Volume	26,359
Open	57.50
Previous Close	57.00
Day's Range	55.10 - 59.20
52-Week Range	46.55 - 98.60
Beta	0.41
RSI	65.73
Earnings Date	Feb 3, 2026

About EQL Pharma AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 21
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EQL

Financial Performance

In 2024, EQL Pharma AB's revenue was 373.52 million, an increase of 41.39% compared to the previous year's 264.17 million. Earnings were 43.12 million, an increase of 89.93%.